{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-23-003162","form_type":"8-K","ticker":"STOK","cik":"0001623526","company_name":"Stoke Therapeutics, Inc.","filed_at":"2023-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.865482+00:00","generated_at":"2026-06-18T11:42:02.934734+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Stoke Therapeutics reports FY2022 net loss $101.1M; STK-001 shows 55% median seizure reduction","bullets":["Net loss for FY2022 was $101.1M ($2.60/share) vs $85.8M ($2.34/share) in 2021; revenue of $12.4M from license agreement.","STK-001 interim analysis: 55% median reduction in convulsive seizure frequency in 6 patients after multiple 45mg doses.","Cash, equivalents, and marketable securities $230.2M at Dec 31, 2022; plus $44.7M raised since, extending runway to end of 2025.","Data from multiple 45mg doses expected mid-2023; 70mg dose data in H2 2023; Phase 3 program planned for 2024.","R&D expenses rose to $77.8M (FY2022) from $54.2M (FY2021) driven by STK-001 and STK-002 development."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-23-003162","json":"https://secwatch.observer/filing/0001564590-23-003162.json","markdown":"https://secwatch.observer/filing/0001564590-23-003162.md","text":"https://secwatch.observer/filing/0001564590-23-003162.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1623526/000156459023003162/0001564590-23-003162-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1623526/000156459023003162/stok-8k_20230306.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T11:42:02.934734+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}